Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New pacing technique could boost heart function in mild failure

NCT ID NCT06126081

Disease control Sponsor: Fu Wai Hospital, Beijing, China Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares a special pacemaker procedure called left bundle branch pacing (LBBP) plus standard heart failure drugs against drugs alone in 36 people with mild heart failure. The goal is to see if early pacing improves the heart's pumping ability more than medication. Participants will be followed for 6 months to measure changes in heart function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Left bundle branch pacing (a pacemaker procedure) plus guideline-directed medical therapy (standard heart failure drugs)
What this could lead to
If successful, this could offer a more effective way to improve heart pumping function and reduce symptoms in certain heart failure patients.
What could go wrong
This is a small, early-stage trial with only 36 participants, so results may not apply widely. The procedure carries risks like infection or lead displacement.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 36 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2023

Expected to finish

Jun 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years; 2. symptomatic heart failure despite guideline-directed medical therapy for at least 3 months, NYHA class II-IV, with an EF between 35% and 50%; 3. complete LBBB meeting Strauss's standard definition 4. Signed informed consent. Exclusion Criteria: 1. Expected survival less than 24 months; 2. Indicated for ICD or pacing therapy; 3. History of VT, VF, or hemodynamic instability; 4. History of mechanical tricuspid valve replacement; 5. Ischemic cardiomyopathy scheduled for CABG and PCI within 3 months; 6. Severe structural heart disease may necessitate cardiac surgery or heart transplantation within 1 year; 7. Pregnancy or planning for pregnancy; 8. Hypertrophic cardiomyopathy or those underwent ventricular septal defect repair, in whom the success of LBBP is anticipated to be challenging; 9. Severe renal dysfunction (eGFR \< 15ml/min\*1.73m\^2).

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Heart failure are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Heart failure Left bundle branch pacing

Contacts and locations

Locations

  • Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, 100037, China

  • The first affiliated hospital of Nanjing medical university

    Nanjing, Jiangsu, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.